Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($1.86), $0.39 better than the analyst estimate of ($2.25). Revenue for the quarter came in at $18.89 million versus the consensus estimate of $18.19 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.